NEVIRAPINE

Post-LOE

nevirapine

Viatris

ANDAORALTABLET, EXTENDED RELEASE

Approved

Oct 2014

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

NEVIRAPINE (nevirapine) by Viatris is non-nucleoside reverse transcriptase inhibitors [moa]. Approved for human immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor [epc]. First approved in 2014.

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

Non-Nucleoside Reverse Transcriptase Inhibitors

Pharmacologic Class:

Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (20)

NCT02116660Phase 2Terminated

Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)

Started Sep 2014

11 enrolled

HIV Infections

NCT02202005Phase 1Completed

Multiple Dose BE Study With Nevirapine 400mg PR Tablets

Started Aug 2014

46 enrolled

HIV-1

NCT02104700Phase 2/3Completed

Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir

Started Apr 2014

150 enrolled

HIV

NCT00002166Phase 3Completed

An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease

HIV Infections

NCT00006396Phase 3Completed

Effectiveness of AZT and Nevirapine in Preventing HIV Transmission From Ugandan Mothers to Their Newborns

1,500 enrolled

HIV Infections

Worked on NEVIRAPINE at Viatris? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.